Barry Bunin, Ph.D.
CEO and Board Director
Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen $50 million in business transactions over the last two decades. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly & Co. Dr. Bunin is on a patent for Kyprolis™ (Carfilzomib for Injection) — a selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma that was widely viewed as the centerpiece of Amgen’s $10.4 Billion acquisition of Onyx Pharmaceuticals.
Dr. Bunin was the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). At Libraria, he led a team that integrated exhaustive reaction capture (synthetic chemistry) with gene-family wide SAR capture (medicinal chemistry). On the scientific side, he co-authored “Chemoinformatics: Theory, Practice, and Products” (Springer-Verlag), a text that overviews modern chemoinformatics technologies, and “The Combinatorial Index” (Academic Press), a widely used text on high-throughput chemical synthesis.
In the lab, Dr. Bunin did medicinal synthetic chemistry developing patented new chemotypes for protease inhibition at Axys Pharmaceuticals (now Celera) and RGD mimics to inhibit GP-IIbIIIa at Genentech. Dr. Bunin received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.
Sylvia Ernst, Ph.D.
Sr. Manager, Commercial Operations
Sylvia Ernst, Ph.D. is the Head of Sales and Sales Operations at Collaborative Drug Discovery, Inc. Dr. Ernst received her Ph.D. in Chemistry in Frankfurt, Germany working in the group of Prof. Dr. Wolfgang Kaim. At that time her research focused on using computational chemistry to find new catalysts for exploiting energy from sunlight.
She has over 20 scientific publications. Interested in chemical information and technology, she joined the Beilstein Institute and was a member of the core team which launched “CrossFire Beilstein”, a database which today is known and used by almost every chemist in the world. From there Sylvia worked in customer-related functions with Beilstein Information Systems, MDL Information Systems, Elsevier MDL, and SciTegic/Accelrys. She joined CDD in 2007.
Sylvia's extensive work with many pharmaceutical and biotech companies as well as academic and government institutions spans the globe, giving her a unique perspective on how the drug discovery and development process is evolving, and how new approaches may impact world health. She joined CDD because she believes that the best response to emerging global health crises is to foster collaborations that join the world's enormous research capabilities into unified efforts.
Director of Product Excellence
Kellan Gregory is CDD's Director of Product Excellence. He has a degree in Chemical Engineering with an emphasis in biotechnology from Tufts University. Kellan was co-author in an HIV study with Dr. Paul A. Volberding, and interned with BioRad and Libraria.
He has not written two books and founded two companies like Barry Bunin, PhD. Unlike Sylvia Ernst, PhD, he did not help with commercial introductions of both Beilstein and Pipeline Pilot. And he’s at least 99 articles and 3 books behind Sean Ekins, Ph.D., who has experience working with two big Pharmas.
But you know what? If you want a product expert with the most experience using data and databases, the strongest people skills and the ability to tell you straight up what will and will not work, Kellan Gregory – with his growing team of specialists in the product group – is your best collaborator. Kellan also creates practical specifications for our product enhancements by prioritizing thousands of requests from hundreds of CDD customers.
Head of Operations EMEA/LATAM
Dr. Vaschetto drives our global collaborations from CDD’s new European Office. Previously she was the VP of Strategic Partnerships, Sales, and Marketing at Dotmatics and held similar executive roles at Perkin Elmer (previously CambridgeSoft). Mariana’s broad experiences span across informatics, chemistry, physics, biology, and communication fields.
She rose through the ranks at Accelrys from responsibilities for support to informatics applications to Chemoinformatics Software Product-Marketing Manager to Senior Product Manager for their complete product line (including data content and software).Mariana has a flair for cooking and knows which way the wind is blowing. Her PhD is in Chemistry.
Chief Technology and Security Officer
Krishna Dole has a decade of experience creating collaborative scientific software. He has developed software for drug discovery, population biology, geomorphology and phylogenetics. Prior to joining CDD in 2007, he coauthored mx, an open source biodiversity informatics application that remains under active use and development.
On the software side, he has been working with the Ruby on Rails framework for over 6 years, and has published a plugin and submitted bugfixes to Rails itself. Like all of CDD's software developers he is an enthusiastic user of automated testing, the agile process, and behavior driven development. At CDD he draws on his broad experience to guide the design and implementation of scientific features. Krishna has a double BA in Biology and Earth Sciences/Environmental Studies from UC Santa Cruz.
Alex Clark, Ph.D.
Alex Clark has been building cheminformatics and computational drug discovery software products since the early 2000's, after spending a decade learning to be a scientist the hard way: running reactions at the lab bench.
Since switching to informatics full time, he has worked on most areas of contemporary chemistry software, whether it be 2D or 3D, large scale (cheminformatics) or small scale (quantum chemistry), big molecules (proteins) or small molecules (drugs). He has a persistent interest in the interface between scientists and software, which continues to challenge our industry, and has done much work on visualization techniques, electronic lab notebooks, and reimagining traditional software for new platforms like mobile, cloud and web.
He publishes regularly in the scientific literature, and has maintained a large number of collaborations since becoming an entrepreneur in 2010. Whenever he is not working on projects for CDD, he continues to maintain his own company, Molecular Materials Informatics, relentlessly experimenting with all manner of future-oriented chemistry software ideas, methods and products. Alex completed his doctorate at the University of Auckland, New Zealand, in 1999, and subsequently relocated to North America.
Director of Customer Engagement
Charlie Weatherall is CDD's Director of Customer Engagement. He attributes his extreme customer dedication to two things. First, he is a true Southern gentleman who cares greatly about other people. Second, he started his career as an R&D end-user of multiple scientific applications and has never forgotten what it's like to "be the customer."
Charlie has over two decades of experience working with industry-leading scientific software companies such as MDL (dating back to ISIS version 0.9 in ’91), SciTegic, Accelrys, CambridgeSoft, and IDBS. He has traveled extensively installing software, providing training, and leading workshops at customer sites and conferences. Customers throughout the world (including Japan, Australia, Great Britain, France, New Jersey, and Illinois) have been known to alter their schedules to match Charlie's availability for visiting their sites. Charlie is looking forward to being the best customer advocate and trusted advisor for the CDD community.
Customer Advisory Board
Jeff Blaney, Ph.D.
Customer Advisory Board
Jeff Blaney is the Director of Computational Chemistry & Cheminformatics at Genentech. Prior to Genentech, Dr. Blaney held executive positions at SGX Pharmaceuticals, Metaphorics, DuPont Pharmaceuticals, and Chiron... just to name a few.
Dr. Blaney obtained his Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco. Dr. Blaney has many years of experience in industrial drug discovery research, focusing on structure-based design, high-throughput docking, combinatorial library design, and chemical informatics.
Henry Johnson, Ph.D.
Customer Advisory Board
Henry W. B. Johnson is Director at Kezar Life Sciences, and was previously a senior member of the medicinal chemistry team at Onyx Pharmaceuticals, Inc., a subsidiary of Amgen. Prior to joining Onyx, he served as a research scientist at Exelixis, Inc. for eight years. During his time there he contributed to several drug discovery programs and he was a primary contributor in the development of four small molecules which entered the clinic.
He obtained his Ph.D. at the University of Utah with Jon Rainier where he completed the synthesis of the natural product gambierol and designed new methodology targeting cyclic ethers. He earned his B.S. in biochemistry from Cal Poly, San Luis Obispo. Dr. Johnson is an author on more than 40 scientific publications and patents. In his current role, he utilizes CDD as a tool to promote a collaborative, nimble, and hypothesis-driven culture.
Thale Jarvis, Ph.D.
Customer Advisory Board
Dr. Jarvis is Chief Scientific Officer at Keystone Symposia. She brings 20+ years of experience in biopharmaceutical drug discovery and development, and is a co-author of 40 publications and over a dozen patents. Dr. Jarvis serves as Principal Investigator on several grants supporting preclinical drug discovery at Crestone, and as scientific liaison with NIAID for Phase I clinical studies of CRS3123 for treatment of Clostridium difficile infections.
From 2009 to 2012, Dr. Jarvis worked at SomaLogic as Director of Technology Development (part-time), and led a structural biology program to characterize modified DNA aptamers with diverse therapeutic and diagnostic applications. Before joining SomaLogic, Dr. Jarvis was Senior Director of Biochemistry at Replidyne (2002-2008), where she played an integral role in multiple antibacterial drug discovery projects, and contributed to both IND and NDA regulatory filings. Her group was responsible for high throughput target-based screening for antibacterial drug leads, and structural and mechanistic characterization of enzyme inhibitors.
In early 2000, Dr. Jarvis co-founded Impact Biosciences, where she served as VP R&D, focusing on target validation in mammalian cell culture systems. Prior to Impact, she served as Associate Director of Biology at Ribozyme Pharmaceuticals, Inc. (RPI) and its spin-off, Atugen USA. At RPI, Dr. Jarvis led discovery efforts for oligonucleotide-based therapeutics in the areas of oncology, arthritis, cardiovascular disease and virology, resulting in two programs that progressed into clinical development. She also served as project leader and scientific liaison for several projects with corporate partners.
At Atugen, she pioneered the development of Atugen’s GeneBlocTM technology for the specific regulation of gene expression, and implemented high throughput screening strategies for validating oncology targets in a variety of human tumor cell lines.
As a research scientist at Synergen (1992-1993), Dr. Jarvis worked on engineering protein-based therapeutics for inflammatory diseases. Dr. Jarvis currently serves as an advisor to the Seattle Structural Genomics Center for Infectious Disease. Dr. Jarvis received her BA degree with distinction in Chemistry from Carleton College in Northfield, MN. She received her PhD in Chemistry from the University of Oregon, where her doctoral work focused on mechanisms of bacteriophage DNA replication.
Paul Humphries, Ph.D.
Customer Advisory Board
Dr. Humphries is Alliance Director of Stanford Innovative Medicines Accelerator. He was previously Chief Scientific Officer at Reset Therapeutics. Dr, and before that a Senior Principal Scientist at Pfizer for 8 years working in the area of Metabolic Diseases. He received his B.Sc. & Ph.D. from the University of Sheffield in the UK and performed postdoctoral research at Florida State University.
While at Pfizer, Dr. Humphries worked on programs resulting in seven IND submissions across four late-stage projects and was responsible for numerous go/no go decisions on early-stage projects. He authored more than 25 scientific articles and patents on a wide range of topics/drug targets and received the Pfizer Global R&D Achievement Award in 2005. Over the course of his Pfizer career,
Dr. Humphries has led or been a member of many successful project teams including:
- Structure-based design of novel peptidyl-propyl-cis/trans isomerase 1 (Pin1) inhibitors for the treatment of cancer.
- Discovery of dual PPARa/? agonists as antidiabetic agents.
- Novel c-Jun N-terminal kinase (JNK) inhibitors for the treatment of Metabolic Syndrome.
- Glucokinase activators for the treatment of Type 2 Diabetes.
- Arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of Type 2 Diabetes.
- Tetrahydroisoquinolin-1-ones as novel G-protein-coupled receptor 40 (GPR40) antagonists for the treatment of Type 2 Diabetes.
- Metabolism-guided design of short-acting Calcium-Sensing Receptor antagonists for the treatment of Osteoporosis.
- Carbazole-containing sulfonamides as Cryptochrome modulators for the treatment of Type 2 Diabetes and Cushing’s Syndrome
Daniel Erlanson, Ph.D.
Customer Advisory Board
Dr. Daniel A. Erlanson is the VP of Chemistry at Frontier Medicines. Prior to that he was the co-founder and President of Carmot Therapeutics, Inc. (http://www.carmot.us). Using a proprietary technology called Chemotype Evolution, Carmot is addressing unmet chemical needs in drug discovery to tackle challenging therapeutic targets. Prior to Carmot, Dr. Erlanson spent a decade practicing medicinal chemistry and advancing techniques for fragment-based drug discovery at Sunesis Pharmaceuticals, which he joined at the company’s inception.
Before Sunesis, he was an NIH postdoctoral fellow with James A. Wells at Genentech. Dr. Erlanson earned his Ph.D. in chemistry from Harvard University in the laboratory of Gregory L. Verdine, where he used chemical, biochemical, and biophysical methods to characterize the interactions between proteins and DNA. He earned his BA in chemistry from Carleton College.
As well as co-editing the first book on fragment-based drug discovery, Dr. Erlanson is an author or inventor on more than forty scientific publications and issued patents. Since 2008 he has been an advisor to the SPARK Translational Research Program at Stanford University. Dr. Erlanson also edits a blog devoted to fragment-based drug discovery, Practical Fragments. He has been a satisfied user of CDD since 2010.
Board of Directors
Alpheus Bingham, Ph.D.
Alph Bingham, Ph.D. is a pioneer in the field of open innovation and an advocate of collaborative approaches to research and development. He is co-founder, and former president and chief executive officer of InnoCentive Inc. Alph spent more than 25 years with Eli Lilly and Company, and brings deep experience in pharmaceutical research and development, research acquisitions and collaborations, and R&D strategic planning.
He was instrumental in creating and developing Eli Lilly's portfolio management process as well as establishing the divisions of Research Acquisitions, the Office of Alliance Management and e.Lilly, a business innovation unit that incubated a wide range of new ventures that exploit open networks,including: InnoCentive, YourEncore, Inc., Coalesix, Inc., Maaguzi, Inc., Indigo Biosystems, Seriosity, Chorus and Collaborative Drug Discovery, Inc.
He currently serves on the Board of Directors of InnoCentive, Fast Track Systems, Inc., and Collaborative Drug Discovery, Inc.; the advisory boards of Navitas Pharma and the Center for Collective Intelligence (MIT), the Business Innovation Factory, and as a member of the board of trustees of the Bankinter Innovation Foundation in Madrid. He serves as a Visiting Scholar at the National Center for Supercomputing Application at the University of Illinois at Champaign-Urbana. He is also the former chairman of the Board of Editors of the Research-Technology Management Journal.
Dr. Bingham was the recipient of The Economist's Fourth Annual Innovation Summit "Business Process Award" for InnoCentive. He was also named as one of Project Management Institute's "Power 50" leaders in October 2005. Dr. Bingham currently participates in the Monitor Talent speaker network. Alph received a B.S. in chemistry from Brigham Young University and a Ph.D. in organic chemistry from Stanford University.
Peter Cohan is the founder and principal of The Second Derivative and the author of the Great Demo! methodology, focused on helping software organizations improve their sales and marketing results – primarily through improving organizations’ demonstrations.
The bulk of his experience is with complex, enterprise software and strategic systems sold to varied audiences in a range of vertical markets. He has enjoyed roles in technical and product marketing, marketing management, presales and presales management, sales and sales management, senior management and the C-Suite - as well as serving on Boards of Directors.
He has delivered thousands of demos – and has been on the receiving end of thousands of demos from a broad variety of vendors around the world, from start-ups to the world’s biggest software vendors, and verticals from accounting to zymology.
In 2003, he authored Great Demo!, a book that provides methods to create and execute compelling demonstrations. The 2nd edition of Great Demo! was published March 2005.
In July 2004, he enabled and began moderating DemoGurus®, a community web exchange dedicated to helping sales and marketing teams improve their software demonstrations, which was subsequently transitioned to the Great Demo! LinkedIn Group in 2010-2011.
Before The Second Derivative, Peter founded the Discovery Tools® business unit at Symyx Technologies, Inc., where he grew the business from an empty spreadsheet into a $30 million per year operation. Prior to Symyx, Peter served in marketing, sales, and management positions at MDL Information Systems, a leading provider of scientific information management software. Peter currently serves on the Board of Directors for Collaborative Drug Discovery, Inc., is an advisor to IN2SV, Inc. and a mentor to StartX, the Stanford University start-up accelerator. He holds a degree in chemistry.
Peter has experience as an individual contributor, manager and senior management in marketing, sales, business development, and as a member of the C-suite. He has also been, and continues to be, a customer.
Board Director, Chairman
Ed Niehaus is the chairman of the board of CDD, and is president and CEO of Cooper, the San Francisco-based design and strategy firm that invented the field of interaction design two decades ago. In the past, Ed has served on the boards of ClickAction, (NASDAQ: CLAC), Avinon and Bio Quiddity and as a board observer of SocialText. Ed joined Cypress Ventures in 2003 and was a general partner until 2006.
Ed was CEO of Niehaus Ryan Wong, Inc., a PR agency, until 2002. NRW helped many Silicon Valley companies, doing its best-known work for Apple (launched Jobs' comeback, the Powerbook & iMac), VeriSign (launched company), Yahoo (first five years) and Pixar (movie launches, Academy Award campaign). As CEO, Ed steered the award-winning agency to become a nearly $20M company with offices in SF, NY, and Austin.
Ed led the development of NRW's Architecture of Identity strategic branding process, in which over thirty of the agency's clients engaged, resulting in clear and actionable definitions of their companies' vision, positioning, and voice. Ed has a BSME degree from Duke University and is a licensed professional engineer.